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Abstract
The family of genuine NF-AT transcription factors consists of four members (NF-AT1 [or NF-ATp], NF-AT2 [or NF-
ATc], NF-AT3 and NF-AT4 [or NF-ATx]) which are characterized by a highly conserved DNA binding domain (is
designated as Rel similarity domain) and a calcineurin binding domain. The binding of the Ca2-dependent phosphatase
calcineurin to this region controls the nuclear import and exit of NF-ATs. This review deals (1) with the structure of NF-AT
proteins, (2) the DNA binding of NF-AT factors and their interaction with AP-1, (3) NF-AT target genes, (4) signalling
pathways leading to NF-AT activation: the role of protein kinases and calcineurin, (5) the nuclear entry and exit of NF-AT
factors, (6) transcriptional transactivation by NF-AT factors, (7) the structure and expression of the chromosomal NF-AT2
gene, and (8) NF-AT factors in Th cell differentiation. The experimental data presented and discussed in the review show that
NF-AT factors are major players in the control of T cell activation and differentiation and, in all likelihood, also of the cell
cycle and apoptosis of T lymphocytes. ß 2000 Elsevier Science B.V. All rights reserved.
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1. The family of NF-AT factors
NF-AT (nuclear factor of activated T cells) was
originally described as a putative transcription factor
in nuclear protein extracts from activated Jurkat T
cells binding to the human interleukin-2 (IL-2) pro-
moter [1]. Soon afterwards, this factor was identi¢ed
as a target for the immunosuppressants cyclosporin
A (CsA) and FK506 [2^5] which are e⁄cient inhib-
itors of T cell activation [6]. Today, four closely re-
lated members of the NF-AT family have been
cloned and characterized in detail. These four NF-
AT proteins, designated NF-AT1^4 (see Fig. 1 and
Table 1 for other names), share a DNA binding do-
main of approximately 300 amino acid residues with
68^73% sequence homology between the various NF-
AT proteins. Due to sequence similarities with the
DNA binding (Rel) domain of Rel/NF-UB factors
which are re£ected in a very similar architecture
(see Section 1.3) the DNA binding domain of NF-
ATs is often designated Rel similarity domain (RSD,
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Fig. 1). Further common features of NF-AT family
members are their strong N-terminal transactivation
domain (TAD-A in Fig. 1) [7,8] and, in particular,
the regulatory domain located between their N-ter-
minal TAD and the RSD.
Recently a gene encoding a novel NF-AT-like fac-
tor has been cloned in three laboratories. This factor,
which was initially isolated as a factor induced by
hypertonicity and, therefore, described as TonEBP
(tonicity enhancer binding protein) [9], was desig-
nated NF-AT5 (or NF-ATz) [10] (S. Miyatake, per-
sonal communication), although it di¡ers signi¢-
cantly from the four genuine NF-AT proteins.
Apart from the RSD which shares 41^45% sequence
similarity with the RSDs of NF-ATs but lacks amino
acid residues contacting AP-1, NF-AT5 neither
shows obvious sequence homology to the N-terminal
TAD or to the calcineurin binding and regulatory
domain typical of genuine NF-ATs. As a conse-
quence, NF-AT5/TonEBP resides constitutively in
the nucleus, is insensitive to a rise in free Ca2
and, therefore, resistant to the action of the immu-
nosuppressants CsA and FK506. Moreover, since
this factor is ubiquitously expressed in numerous
cells (and not predominantly expressed in lympho-
cytes, like NF-AT1 and 2), unable to interact with
AP-1 (Jun/Fos) and to transactivate an NF-AT-de-
pendent reporter gene [9,10] it is a matter of dispute
whether or not TonEBP/NF-AT5/NF-ATz should be
included within the family of NF-AT transcription
factors.
1.1. Structure of NF-AT proteins
The structures of NF-AT proteins are schemati-
cally compiled in Fig. 1. All NF-AT proteins are
characterized by the presence of a highly conserved
RSD which harbors the sequence motifs for DNA
binding, interaction with AP-1 and, as shown for
NF-AT2, one nuclear localization signal [11]. More-
over, they contain a regulatory domain in front of
the RSD and at least one TAD near the N-terminus.
The regulatory domain harbors numerous phosphor-
ylation sites which are organized in the conserved
serine-rich domain (SRD) and three so-called SP mo-
tifs. These sites are substrates for several Ser/Thr
protein kinases and of the protein phosphatase calci-
neurin which binds to this region (see Section 2.1). In
addition, one nuclear localization signal (NLS) and
one nuclear export signal (NES) have been identi¢ed
to lie in this domain of NF-AT2 [11,12]. It is very
likely that, due to a spatially restricted dephosphor-
ylation by calcineurin, the NLSs of NF-AT factors
are exposed and bound to the nuclear import ma-
Table 1
Phenotype of NF-AT-de¢cient mice
Factor Expression Phenotype of NF-AT-de¢cient mice
NF-AT1
(NF-ATp, NF-ATc2)
Constitutive synthesis in
numerous cells ; high expression
in peripheral lymphocytes
Hyperproliferation; increase in number of peripheral lymphocytes
and size of spleen and lymph nodes; enhanced GC formation; no
involution of the thymus; enhanced immune responses; incomplete
termination of superantigen stimulation; modulation of Th2
lymphokine synthesis ; no defect in IL-2 synthesis; aberrant
chondrogenesis by increased expression of cartilage markers
NF-AT2
(NF-ATc, NF-ATc1)
Inducible synthesis, particularly
in T e¡ector cells ;
high expression in peripheral
lymphocytes
Defects in generation of cardiac valves and septa: mice die before
day 13.5 of development in utero; RAG3=3 mice containing NF-
ATc-de¢cient lymphocytes showed reduced number of thymocytes,
impaired proliferation, impaired synthesis of Th2 lymphokines
NF-AT4
(NF-ATx, NF-ATc3)
Constitutive synthesis ;
high expression in thymus
Defects in positive selection of thymocytes; increase in apoptosis
of double positive thymocytes and hyperactivation of T cells ;
impaired expression of bcl-2
NF-AT1+4 See above Drastic increase in the synthesis of Th2 lymphokines; impaired
synthesis of Th1 lymphokines; hyperproliferation of peripheral
lymphocytes and splenomegaly; impaired Fas-mediated apoptosis;
constitutive nuclear localization of NF-AT2/A
Compiled according to [39^41,50,63,120,128] for NF-AT1, [42,43,116,117] for NF-AT2, [129] for NF-AT4 and [44] for NF-AT1+4
double-de¢cient mice.
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chinery, thereby mediating the nuclear entry of NF-
AT factors (see Section 2.2). Similarly, the NES of
NF-ATs might be hidden in DNA-bound, transcrip-
tionally active NF-AT factors, only to be exposed
after a decrease in nuclear calcineurin and an in-
crease in NF-AT kinase activity which leads to a
release of NF-AT from DNA and its nuclear export.
All NF-AT factors appear to be synthesized in
several isoforms which can di¡er in both their N-
and C-terminal peptides [13^18]. Similar to NF-
AT1 and NF-AT4, NF-AT2 is synthesized in three
major isoforms which di¡er markedly in the length
of their C-termini. Interestingly, the C-terminal extra
peptides of the longest isoform NF-AT2/C harbor a
second, albeit weak TAD which shares approxi-
mately 30% homology with the C-terminal sequence
of NF-AT1 [19]. These sequences in NF-AT1 also
harbor a TAD [7]. Although the presence of a second
TAD in NF-AT2/C, as compared to a single N-ter-
minal TAD in NF-AT2/A, suggests a special func-
tion for this isoform, only subtle di¡erences were
detected in the activities between both isoforms in
transient transfection assays using three lymphokine
promoters [19]. This situation di¡ers from the signi¢-
cant di¡erences in the activities of individual NF-
AT4/x isoforms. In isoform NF-ATx1, a strong
TAD was identi¢ed within 15 amino acids near its
C-terminus which are highly conserved among all
NF-AT factors. Deletion of this C-terminal peptide
led to a strong decrease in NF-ATx1 activity after
transfection into 293 HEK and T cells [16,20].
1.2. The DNA binding of NF-AT factors and their
interaction with AP-1
NF-AT1 and 2 show a sequence homology of 73%
in their RSDs and somewhat less than 20% homol-
ogy to the Rel domains of Rel/NF-UB factors [21].
Fig. 1. Schematic structure of NF-AT factors. The DNA binding regions of NF-ATs, the RSD, are shown as black boxes. The N-
and C-terminal transactivation domains, TAD-A and TAD-B, are drawn in red. Further sequence motifs are shown for NF-AT2 only
where TAD-B consists of two peptides which are separated by an inhibitory domain [19]. For the regulatory domain located between
TAD-A and the RSD, the position of the serine-rich region (SRR) and of SP motifs 1^3 are indicated. In addition, binding regions
for the transcriptional co-factor CBP and the Ca2-dependent phosphatase calcineurin as well as signals for nuclear localization
(NLS) and nuclear export (NES) of NF-AT2 are shown. The structure of NF-AT5/TonEBP corresponds to the human protein pub-
lished by [9,10]. NF-AT1/p/c2 was cloned ¢rst by McCa¡rey et al. [124], NF-AT2/c/c1 by Northrop et al. [21], NF-AT3/c4 by Hoey
et al. [125], and NF-AT4/x/c3 by Masuda et al. [126] and Hoey et al. [125], respectively.
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However, the DNA binding regions of both types of
factors show a similar solution and crystal structure
[22^24]. Very similar to the Rel domains, the RSDs
of NF-ATs are organized in 10 L-strands which are
separated by two extended loops as shown in Fig.
2A. The amino acid residues of the ¢rst loop which
links the A and B L-strands of the L-barrel are re-
sponsible for DNA binding [25]. Among the 25 res-
idues of the DNA binding loop (DBL) the two res-
idues Arg448 and Arg439 in NF-AT2 (or Arg430
and Arg421 in NF-AT1) participate in hydrogen-
bond interactions with O6 and N7 of two G nucleo-
tides, G1 and G2, of the NF-AT core motif (see Fig.
2B). In addition, the Tyr residue 442 in NF-AT2 (or
424 in NF-AT1) forms van der Waals contacts with
the neighboring two T nucleotides of the NF-AT
motif. In contrast to these major groove contacts
of DBL, the DNA binding of NF-ATs is further
stabilized by minor groove contacts [22^24]. How-
ever, these contacts are not mediated by the DBL
but by the GP-H loop (or E-F loop according to
another nomenclature [24], also designated insert re-
gion) which, on the other hand, provides the surface
for numerous contacts with the Jun/Fos heterodimer
(see also [26]). In c-Jun, the Arg285 residue was
mapped to be in close contact with the insertion
region and found to be essential for the interaction
with NF-AT [22,27]. In addition, at 2.7 Aî resolution
the crystal structure of NF-AT/AP-1 complexes re-
vealed a few more residues in c-Jun which contact
the DBL in NF-AT1 whereas approximately a dozen
residues in c-Fos were observed to be in contact with
NF-AT1, either with its DBL or with other portions
of NF-AT [24].
Surprisingly, the multitude of contacts between the
NF-AT and AP-1 proteins are not strong enough to
mediate complex formation between NF-AT and
AP-1 in solution. However, the mutual contacts fa-
cilitate the coordinate binding of NF-AT and AP-1
to composite NF-AT/AP-1 DNA motifs. The pres-
Fig. 2. Structure of the DNA binding domain (the RSD) of NF-AT2 and its contacts to the NF-AT core binding motif GGAAAA.
(A) Topological map of RSD of NF-AT2 (modi¢ed according to [22]). The 10 L-strands are shown as black arrows. Between the A
and B L-strands lies the DNA binding loop (DBL) which forms the majority of contacts to the NF-AT DNA motif. The insert region
which harbors the majority of contact points to the AP-1 Jun/Fos heterodimer and some to DNA is also indicated and is located be-
tween the GP and H L-strands. (B) Contacts of RSD from NF-AT2 with the NF-AT core motif (modi¢ed according to [23]). The two
residues Arg448 and Arg439 which are part of the DNA binding loop participate in hydrogen interactions with the G1 and G2 nu-
cleotides of the NF-AT motif, respectively. Tyr442 forms van der Waals contacts with the T3P and T4P nucleotides on the opposite
strand of the motif while further contacts are formed between the T5P and T6P nucleotides and amino acid residues of the NF-AT in-
sert region which contact the NF-AT DNA motif in its minor groove [24].
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ence of NF-AT on the distal IL-2 NF-AT site sta-
bilizes the binding of AP-1 to this non-consensus AP-
1 (TRE) site approximately 10-fold and converts it to
a ‘superconsensus’ TRE which binds AP-1 more
tightly than a consensus TRE [27]. Similarly, the
complex formation between NF-AT and AP-1 on
Pu-bd is approximately 10-fold more stable than
the binding of NF-AT alone to this site [28] indicat-
ing the mutual stabilization in the binding of both
factors to a composite NF-AT/AP-1 site which is
typical for the IL-2 promoter and numerous other
lymphokine promoters [29].
A direct protein^protein interaction between the
RSD of NF-AT3 and the second zinc ¢nger of
GATA-4 has been described to enhance cardiac tran-
scription [30]. A similar interplay between GATA-3
and NF-AT2 seems also to stimulate transcription in
Th2 cells, such as in the activation of proximal IL-5
promoter (Klein-Hessling et al., in preparation). This
suggests that depending on the tissues where NF-AT
factors are expressed and the promoter context NF-
AT factors can interact with factors others than AP-
1.
1.3. NF-AT target genes
Numerous, if not all lymphokine promoters which
are activated upon T cell activation contain multiple
NF-AT binding sites. These sites are mostly compo-
site NF-AT+AP-1 binding sites of structure 5P-
caxwGGAAAawxxxg/aTGAC/GTCAg/tc-3P (where
capital letters denote highly, lower case letters poorly
conserved nucleotides; w = A or T; x = any nucleo-
tide), or slightly modi¢ed versions of this sequence.
Remarkably, such sites were found to be approxi-
mately 10-fold more frequent in promoters of genes
which are expressed upon activation of T cells than
in genes active in other tissues [29].
In the human and murine IL-2 promoters which
span approximately 300 bp of immediate upstream
DNA (see [31,32] for reviews) two high a⁄nity NF-
AT sites have been determined [3]. These are located
around the nucleotide positions 3145 and 3285 and
carry the NF-AT core motif GGAAA. Introduction
of mutations into these sites which abolished NF-AT
binding had a deleterious e¡ect on promoter induc-
tion [33]. The distal NF-AT site, also designated
ARRE2 [1] or Pu-bd for the murine IL-2 promoter
[34], is the prototypical NF-AT binding site which
has been used in the majority of studies on NF-AT
function. In addition, three very low a⁄nity NF-AT
binding sites have been described to be located
around the positions 345, 390 and 3160 within
the IL-2 promoter [35]. The latter overlaps with the
so-called CD28 responsive element [36], and an in-
crease of NF-AT binding was observed after stimu-
lation of T cells by antibodies directed against CD28
[37,38]. Surprisingly, inactivation of neither the NF-
AT1 nor the NF-AT2 gene led to a reduction in IL-2
RNA and protein synthesis of T cells [39^43]. How-
ever, splenocytes de¢cient for both NF-AT1 and NF-
AT4 showed a decrease to about 30% in IL-2 secre-
tion relative to wild-type cells [44], suggesting that all
three NF-AT factors exert overlapping functions in
the control of IL-2 promoter activity.
Four (to ¢ve) NF-AT binding sites are also part of
the human and murine IL-4 promoters ([45^47]; see
[48] for a recent review). Mutations in the NF-AT
core motifs from two of them, i.e. either in the P1/
Pu-bB or in the P4/Pu-bD/PRE-I site, resulted in a
strong decrease in IL-4 promoter induction whereas
mutations in the other two sites had a less dramatic
e¡ect [45]. P1/Pu-bB and P4/Pu-bD/PRE-I are com-
plex binding sites to which C/EBP, Octamer and AP-
1 proteins can bind, in addition to NF-AT [45,47,49].
Similar to the most proximal NF-AT site of the IL-2
promoter (the 345 site) the corresponding P0/Pu-bA
of the IL-4 promoter corresponds to a site where
NF-AT binds without AP-1 [45,35]. Contrary to
IL-2 synthesis which remained intact in T cells de¢-
cient for NF-AT2, a clear-cut defect in synthesis of
IL-4 and other Th2-type lymphokines was observed
[42,43]. Surprisingly, inactivation of the NF-AT1
gene led to an increase in expression of IL-4 and
other Th2-type lymphokine [39,40,50] which was
found to be strongly enhanced in mice in which
both the NF-AT1 and NF-AT4 genes were inacti-
vated [44] (see Section 4.2).
One NF-AT binding site is located around posi-
tion 3115 within the IL-5 promoter (see [48,51])
whose induction is strongly enhanced by high levels
of cAMP in T cells [52,53]. This might be due to the
collaboration of NF-AT with GATA-3 and Ets-like
factors which bind to and control the activity of IL-5
promoter in T cells (S. Klein-Hessling et al., in prep-
aration) but not of IL-2 and IL-4 promoters whose
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induction is either reduced (IL-2) or only slightly
enhanced (IL-4) by elevated cAMP concentrations.
Additional NF-AT sites appear to be located further
upstream and seem also to be involved in IL-5 reg-
ulation [54].
Further cytokine genes which have been shown to
be controlled by NF-AT-dependent promoters/en-
hancers are the interferon-Q (IFN-Q), IL-3, granulo-
cyte/macrophage colony-stimulation factory (GM-
CSF) and tumor necrosis factor K (TNFK) genes
[55^58]. The induction of the human TNFK promoter
in both T and B cells appears to be controlled by
NF-AT factors [59]. One site important for TNFK
promoter induction in T cells is the so-called U3 site.
It contains an NF-UB-like sequence motif which is
bound by an NF-ATp dimer, assisted by an ATF-
2/Jun heterodimer which binds to a CRE (cAMP-
responsive element) motif situated 5P of the NF-AT
non-consensus motif [58,60,61]. Four NF-AT bind-
ing sites were detected within a 360 bp fragment of
the IL-3 enhancer located 14 kb upstream of the hu-
man IL-3 gene. One of them (IL190) overlaps with
an Octamer binding site. Although both factors do
not cooperate in their DNA binding to this motif
they synergistically act through this site [57]. Four
(to ¢ve) NF-AT binding sites are also part of the
human GM-CSF promoter spanning approximately
550 bp of immediate upstream region of the gene.
Interestingly, the two sites that contain a non-con-
sensus AP-1 site 3P of the NF-AT core motif exhibit
a strong NF-AT binding while the two sites contain-
ing AP-1 consensus sites are less e⁄cient in NF-AT
binding [62].
Lymphokine and cytokine genes are not the only
genes which are controlled by NF-AT factors in T
cells. Two NF-AT sites have been identi¢ed within
the CD25/IL-2 receptor K promoter [63], and NF-AT
factors were also reported to bind to and control the
activity of Fas ligand and CD40 ligand promoters
[64^66]. The expression of transcription factors
Egr2 and Egr3 which are predominantly expressed
in Th1 cells and contribute to FasL expression
[65,67] is also controlled by NF-AT. While in
CD4 T cells de¢cient for NF-AT1 or 4 a weak
reduction in RNA levels of both factors was ob-
served, T cells from double-de¢cient mice synthesize
only trace amounts of both Egr RNAs [65]. The
promoters of the chromosomal NF-AT2 gene them-
selves contain a number of NF-AT core binding mo-
tifs (S. Chuvpilo, unpublished data), suggesting that
NF-AT factors might control the expression of NF-
AT2.
Composite NF-AT+AP-1 binding sites have been
detected in a large number of diverse promoters and
enhancers controlling genes which encode proteins as
di¡erent as tyrosine and serine/threonine protein ki-
nases, Ca2 binding proteins and proteins controlling
the cell cycle and apoptosis [29]. We have observed
that in collaboration with c-Myb, NF-AT factors
bind to and control the proximal promoter of the
p56lck gene (C. Stibbe, A. Avots et al., in prepara-
tion) which is most active in thymocytes. However,
for the majority of other promoters it remains to be
demonstrated whether or not they are bound and
controlled by NF-AT or, e.g., Ets transcription fac-
tors which bind to similar sequence motifs.
2. Activation of NF-AT factors
2.1. Signalling pathways leading to NF-AT
activation: the role of protein kinases and
calcineurin
The e⁄cient transcriptional activation of NF-AT
factors in T cells needs at least two signals which are
provided by activation of the T cell receptor (TCR).
These TCR-mediated signals lead to (1) a rise in
intracellular free Ca2 and calcineurin activation,
and (2) the stimulation of several protein tyrosine
kinases, e.g. p56lck, and p21ras and other small
GTP binding proteins which activate a number of
Ser/Thr protein kinase cascades (Fig. 3). While the
activation of calcineurin mediates the nuclear trans-
location of NF-AT factors [6,68], activation of clas-
sical Ras/Raf/Erk and further protein kinase cas-
cades controls the transcriptional activation of NF-
ATs [8] and the induction of AP-1 [69] (see Fig. 3).
The two immunosuppressants CsA and FK506 in-
hibit T cell activation by blocking Ca2-dependent
signalling pathways [70]. They bind to low molecular
weight intracellular receptor proteins, so-called im-
munophilins. In lymphocytes, cyclophilin A is the
most common immunophilin binding to CsA while
FKBP12 is the major partner of FK506. Such heter-
odimeric CsA/cyclophilin A (or FK506/FKBP12)
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complexes bind with high a⁄nity to the phosphatase
calcineurin, PP2B, and inhibit its Ca2/calmodulin-
depending activity [71]. Calcineurin consists of two
polypeptides, a large, catalytic subunit A of 59 kDa
and subunit B of 19 kDa, and exerts a number of
divergent cellular functions by binding to IP3, rya-
nodine and transforming growth factor-L receptors
[72^74]. Further important targets are the NF-AT
factors. Numerous studies have shown that calci-
neurin binds to and dephosphorylates NF-AT pro-
teins thereby inducing their transport into the nu-
cleus [75].
Calcineurin directly interacts with several portions
of the regulatory region of NF-AT factors [20,76,77].
Fig. 3. Activation of NF-AT factors. T cell receptor (TCR) stimulation leads to the rapid activation of protein tyrosine kinases
(PTKs), in particular of p56lck, and a rise in free, intracellular Ca2. One downstream event of activation of PTKs is the generation
of active, GTP-bound form of p21ras which, in turn, activates downstream kinase cascades, such as the Raf-MEK-Erk cascade. A rise
in intracellular free Ca2 and calmodulin stimulates calcineurin (PP2B) activity which is crucially involved in the nuclear import and
export of NF-AT factors. It is thought that calcineurin-mediated dephosphorylation of regulatory region (RR) of NF-AT factors un-
masks NLSs (see Fig. 1) and leads to their nuclear translocation. Both the Ser/Thr-speci¢c protein kinases GSK3, CKI, CKII and
JNK have been described to phosphorylate NF-AT2 and/or NF-AT4, respectively, and to counteract calcineurin activity. These pro-
tein kinases and calcineurin appear to bind to NF-AT, to be translocated into the nucleus and to mediate the nuclear export of NF-
AT.
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For NF-AT4, two regions have been mapped to ami-
no acid residues 25^143 and 321^406 [78]. The more
N-terminal peptide contains a version of the
SPRIEIT motif which spans amino acids 110^116
in murine and human NF-AT1 (and 117^123 in
NF-AT2) and was found to be essential for the ef-
fective recognition and dephosphorylation of NF-
AT1 by calcineurin [79]. By using an a⁄nity-driven
peptide selection procedure a modi¢ed form of
SPRIEIT was synthesized, designated VIVIT, which
was approximately 25-fold more e¡ective in inhibit-
ing the binding of calcineurin to NF-AT1 [80]. Ex-
pression of a chimeric GST-VIVIT protein e⁄ciently
inhibited the calcineurin-dependent nuclear translo-
cation of NF-AT1 and the activation of an NF-
AT/AP-1-driven reporter gene but did not impair
calcineurin activity. Thus, VIVIT allows the distinc-
tion between NF-AT and calcineurin function and,
therefore, to determine NF-AT- (and not calcineu-
rin-) speci¢c target genes (see [80,81]).
All genuine NF-AT proteins are bound by calci-
neurin and appear to be dephosphorylated in a sim-
ilar, if not identical manner. Upon dephosphoryla-
tion of several phosphoacceptor sites the NF-AT/
calcineurin complexes are translocated into the nu-
cleus [82] where they stimulate transcription. This
needs persistent high levels of free cellular Ca2 pro-
viding sustained Ca2 signals [83] since otherwise the
active NF-AT/calcineurin complexes dissociate, and
the NF-AT proteins (and calcineurin) are rapidly
exported to the cytosol (see Fig. 3).
Several Ser/Thr protein kinases have been de-
scribed to phosphorylate NF-AT proteins, thereby
counteracting the activity of calcineurin, among
them glycogen synthase kinase-3 (GSK-3) and casein
kinase IK (CKIK). Crabtree and colleagues [84] pu-
ri¢ed from brain protein extracts a GSK-3-like enzy-
matic activity which phosphorylated the NF-AT2
peptide 196^304 but not a mutated version in which
all serines were substituted by alanines. GSK-3 pre-
fers to phosphorylate serines adjacent to serines
which were phosphorylated previously by protein ki-
nase A (PKA). Consequently, PKA and GSK-3 (but
not one of the two kinases alone) led to a stoichio-
metric phosphorylation of NF-AT2. In addition,
very similar phosphopeptide patterns were observed
for NF-AT2 phosphorylated in vivo or in vitro by
PKA+GSK-3. Expression of GSK-3 in COS cells
suppressed the Ca2-calcineurin-induced nuclear
translocation of co-expressed NF-AT2, whereas ex-
pression of several other kinases (e.g. casein kinase
II, Erk, PKA and protein kinase C) was less e¡ective
in this respect. In line with its function as an NF-AT
kinase, GSK-3 stimulated the re-export of NF-ATc
in the same cells [84].
Several lines of evidence suggest that GSK-3 is not
the only protein kinase controlling the nuclear im-
port and export of NF-AT2 and other NF-AT mem-
bers. In a study published recently, Clipstone and
colleagues [85] reported that the MAP/SAP kinases
Erk1, JNK3 and p38K as well as casein kinase II
(CKII) physically interact with and phosphorylate
the regulatory domain of NF-AT2, thereby inhibit-
ing the nuclear transport of NF-AT2. Important
phosphoacceptor sites are the serine residues 172
and 187 of the serine-rich region (SRR; see Fig. 1)
whose mutation leads to the constitutive nuclear
transport of NF-AT2 whereas mutations within the
three SP motifs impaired NF-AT2’s nuclear export.
A suppressive e¡ect on nuclear translocation of NF-
AT4 was described for JNK which binds near the N-
terminus of NF-AT4 (and not NF-AT3) and phos-
phorylate it at serines 163 and 165 [86]. This ¢nding
supports the observation that resting T cells from
JNK1-de¢cient mice showed constitutive nuclear ac-
cumulation of NF-AT2 which appeared to contrib-
ute to the hyperproliferation and preferential Th2
cell development observed for JNK1-de¢cient T cells
[87].
Zhu et al. [88] proposed a role for CKI in control-
ling the phosphorylation and nuclear transport of
NF-AT4. CKIK was found to associate with amino
acids 177^184 and to phosphorylate this domain in
vitro and in vivo at additional phosphoacceptor sites
located further downstream, whereas overexpression
of a dominant negative version of CKIK was able to
suppress NF-AT4 phosphorylation. In addition,
MEKK1, an upstream kinase of stress signal path-
ways, was found to stabilize the interaction between
CKIK and NF-AT4 and, therefore, to suppress the
nuclear import of NF-AT4 [88]. It is worth mention-
ing that phosphorylation of Ser172 (e.g. by Erks or
JNKs) and of further serines of SRR create perfect
consensus phosphorylation sites for CKI which pre-
fers to bind to substrates containing phosphoserines
or phosphothreonines at amino acid position 33.
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These closely linked phosphoacceptor sites could cre-
ate the substrate for a chain of hierarchical phos-
phorylation events described to be typical for both
CKI and CKII ([89]; see also [85] for a discussion).
2.2. Nuclear entry and exit of NF-AT proteins
The rapid nuclear entry and exit of NF-AT pro-
teins which take place within 5^10 min after T cell
activation is controlled by the phosphorylation state
of the regulatory, calcineurin binding region (see [68]
for a discussion). Mutation of serines to alanines in
several phosphoacceptor sites of NF-AT2, in either
the SRR or the SP motif, led to its constitutive nu-
clear import [11], and deleting the Z domain (aa 187^
236) in NF-AT4 resulted in a similar e¡ect [88].
Among the putative NLSs within NF-AT2, two of
them, spanning the amino acid residues 263^271 and
681^685, were found to mediate nuclear import when
fused to the cytosolic GTP/GDP exchange factor
SOS. Mutation of underlined basic residues within
the putative NLS1, CNKRKYSLN, at 263^271 to
QIL reduced the nuclear localization to 60% of the
wild-type level whereas mutation of the KRKK mo-
tif (in NLS2) at positions 682^685 to TRTC was
without e¡ect. However, mutation of both motifs
completely blocked the nuclear import of NF-AT2.
Depending on the phosphorylation of SP motifs and,
in particular, of SRR, the RSD bearing NLS2 was
found to interact in vitro with the N-terminal half of
matrix-bound NF-AT2 (amino acids 2^418). No in-
teraction was observed when the NLS2 motif was
mutated. These data suggest that in the cytoplasm
the NLSs of NF-AT2 are masked by binding to the
phosphorylated SRR and SP motifs, and dephos-
phorylation leads to the unmasking of one or two
redundant NLSs and the nuclear translocation of
NF-AT [11]. In essence, a similar model was pro-
posed in [88] suggesting a masking of NLS1 by the
phosphorylated Z domain in NF-AT4 spanning the
SP1 motif.
As mentioned above, NF-AT4vZ, an NF-AT4
mutant lacking the Z domain, is constitutively trans-
ported to the nucleus. Overexpression of Crm1
( = exportin 1), a receptor mediating the nuclear ex-
port of proteins carrying an NES rich in leucines
[90], led to the exit of NF-ATvZ to the cytoplasm
[91]. This process could be inhibited by calcineurin,
apparently by competing with Crm1 for binding to
NF-AT4 and masking an NES within NF-AT4.
Crm1 was found to bind to two sequences near the
NF-AT4 N-terminus (spanning the positions 31^96
and 99^154, designated NES1 and NES2, respec-
tively) which are also bound by calcineurin. These
data led to the assumption that Crm1 and calcineur-
in control the length of nuclear residence of NF-ATs
and, therefore, the transcriptional activation of NF-
AT target genes by competing for NF-AT binding
[91].
Fusion of several NES-like peptides from NF-AT2
to a nuclear Gal4 protein resulted in the identi¢ca-
tion of an NES in NF-AT2 spanning its amino acids
310^321 [12]. While the substitution of hydrophobic
leucine and isoleucine residues of NES by alanines
impaired the nuclear export of NF-AT2 it did not
a¡ect its nuclear translocation and overall phosphor-
ylation state. However, contrary to the high sequence
conservation of basic residues within the NLS1 (at
263^271) between the NF-AT proteins, the hydro-
phobic residues of NES from NF-AT2 are not con-
served, implying that various NES motifs located at
di¡erent positions could be involved in controlling
the nuclear export of individual NF-AT proteins
(see [68,92] for further discussion).
2.3. Transcriptional transactivation by NF-AT factors
Compared to the numerous studies on the nuclear
translocation of NF-AT factors there are only a few
investigations of their ability to transactivate tran-
scription. Studying the transcriptional potency of
various segments of NF-AT1 by fusing them to the
DNA binding domain of the yeast transcription fac-
tor Gal4, two TADs were identi¢ed, one spanning
amino acid residues 1^145 and one within the C-ter-
minal region [7]. The N-terminal TAD of NF-AT1
which is rich in acidic residues and proline is bound
by p300/CBP [93], a transcriptional co-factor which
exerts histone transacetylase activity and serves as a
molecular platform for the assembly of further fac-
tors involved in transcriptional control (see [94] for a
review). A strong transactivation domain was found
to be part of the C-terminal region of isoform NF-
ATx1 spanning 15 amino acids which are highly con-
served between all NF-AT factors. Other isoforms of
NF-ATx ( = NF-AT4) lacking this peptide showed
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only about one third of the transcriptional activity of
NF-ATx1 [16].
Similar to NF-AT1, the longest isoform of NF-
AT2, NF-AT2/C, harbors two TADs, one strong
N-terminal TAD, TAD-A spanning amino acids
113^204 [8], and a weaker one, TAD-B, spanning a
large portion of the C-terminal region [19]. TAD-B
consists of two subdomains which are separated by a
short peptide which is able to suppress transcription.
Although the two TADs di¡er in their state of phos-
phorylation they are activated by identical stimuli
[19]. This might be due, at least in part, to the bind-
ing of p300/CBP which was shown to associate with
TAD-A and to control the mode of its induction [8].
TAD-A is constitutively bound to p300/CBP, and the
inducible phosphorylation at Ser117 a¡ects neither
this interaction nor the transcriptional activity of
TAD-A. However, several inducers of MAP/SAP ki-
nase cascades, such as phorbol ester, UV light and
methyl methanesulfonate (but not ionomycin which
increases free Ca2), as well as constitutively active c-
Raf and Rac were able to synergistically induce
TAD-A+p300 activity suggesting that these signal-
ling cascades stimulate TAD-A through p300/CBP
and possibly further co-factors [8].
In summary, the studies available today indicate
that in NF-AT/AP-1 complexes both partners, NF-
AT as well as AP-1, contribute to transcriptional
activation. The strong N-terminal TAD of NF-ATs
( = TAD-A) overlaps with their calcineurin binding
regulatory region. It remains to be shown how the
binding of active calcineurin to NF-AT, necessary to
keep NF-AT in the nucleus, and the phosphorylation
state of the regulatory region contribute to NF-AT
transactivation. The notion that calcineurin-mediated
dephosphorylation events induce an unmasking and
‘release’ of speci¢c NF-AT signalling motifs (e.g. the
NLSs) thus allowing nuclear transport of NF-AT
[11,88] might also apply for the transcriptional acti-
vation by NF-AT factors.
3. Structure and expression of the chromosomal
NF-AT2 gene
While NF-AT1 and NF-AT4 are constitutively
expressed in T cells (see [75]) transcription of the
chromosomal NF-AT2 gene is strongly induced
upon T cell activation [21]. In primary T e¡ector
cells, TCR activation additionally leads to a switch
from the synthesis of two longer NF-AT2 isoforms,
B and C, to the synthesis of the short isoform NF-
AT2/A. In part this is due to the use of an intragenic
weak poly(A) site, pA1, which is inactive in naive
T cells and of weak activity in resting T e¡ector cells.
In these cells the stronger distal poly(A) site, pA2, is
predominantly used which results in the generation
of the two longer isoforms, B and C [17].
In addition to their C-terminal heterogeneity, NF-
AT2 proteins also di¡er in the lengths of their N-
termini. Two types of NF-AT2 cDNAs were cloned,
encoding individual N-terminal peptides of 42 and 29
amino acid residues, respectively [17,18]. This obser-
vation and recent reports on the loading of RNA
polymerase II with splicing and poly(A) factors at
a gene’s promoter (see [95] for a review) led us to
assume that the alternative polyadenylation events in
NF-AT2 synthesis are controlled by two promoters,
an inducible promoter, P1, and a constitutively active
promoter, P2. As illustrated in the model shown in
Fig. 4A, we speculated that the inducible, stronger
promoter P1 collaborates with the intragenic, weak
poly(A) site pA1, thereby controlling the inducible
synthesis of the short isoform NF-AT2/A. On the
other hand, the constitutively active and relative
weak promoter P2 collaborates predominantly with
the strong distal poly(A) site pA2 and controls the
generation of longer isoforms NF-AT2/B and C ex-
pressed in naive and resting T cells. Studies on the
expression of the chromosomal murine NF-AT2 gene
which we have cloned suggest that this might indeed
be the case (S. Chuvpilo, E. Jankevics et al., in prep-
aration).
The schematic structure of the chromosomal mur-
ine NF-AT2 gene is shown in Fig. 4B. The NF-AT2
gene spans approximately 100 kb of DNA and is
split into 11 exons. As predicted, the transcription
of the gene in T cells is controlled by two promoters,
P1 and P2. RNase protection assays indicated that
promoter P1 remains inactive in non-induced cells
but is strongly induced after activation in primary
murine T cells and EL-4 thymoma cells. In contrast,
P2 was found to be active in uninduced cells of both
types of T cells, and its activity did not increase after
T cell activation. Usage of P1 leads to an alternative
splicing event which results in skipping exon 2 se-
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quences which become expressed only when tran-
scription starts downstream of the promoter P2 (S.
Chuvpilo et al., in preparation).
Which promoter cooperates predominantly with
which poly(A) site is still an open question. We as-
sume that the constitutively active and relatively
weak P2 promoter is ine¡ective in generating NF-
AT2/A transcripts, i.e. to collaborate with the intra-
genic weak poly(A) site pA1. This site might only be
used under high concentrations of poly(A) factors
which are provided when the inducible, stronger pro-
moter P1 is active. At P1, RNA polymerase II might
be loaded with large amounts of poly(A) factors
which are necessary to recognize and to stimulate
the activity of weak pA1 site. Experiments are in
progress to test this hypothesis and to analyze the
Fig. 4. Scheme of structure and expression of the chromosomal NF-AT2 gene. (A) Model of expression of chromosomal NF-AT2
gene. In T lymphocytes the chromosomal NF-AT2 gene is transcribed into three major mRNAs encoding the short isoform NF-AT2/
A and the longer isoforms NF-AT2/B and C [19]. NF-AT2/A is predominantly synthesized in T e¡ector cells after stimulation while
the isoforms B and C are constitutively synthesized in naive T cells and resting T e¡ector cells. We have shown that the relatively
weak poly(A) site, pA1, contributes to the generation of NF-AT2/A and the distal pA2 site to the generation of NF-AT2/B and C
[17]. We assume that the activity of inducible promoter P1 is correlated with the use of pA1 in T e¡ector cells and that of the consti-
tutive promoter P2 with the use of pA2 in naive and resting T cells. (B) Structure of the chromosomal NF-AT2 gene. The position
and size of 11 exons (in nucleotides), the two promoters P1 and P2 and the two poly(A) sites pA1 and pA2 are indicated. (Since so
far the murine NF-AT2 gene has not been completely sequenced in its 3P portion we show here a ‘chimeric murine/human NF-AT2
gene’ consisting of parts of murine and human genes as indicated. However, apart from the existence of two pA1 elements leading to
two NF-AT2/A RNAs with mRNAs tails of di¡erent lengths the 3P portion of the murine gene is very similar in its structure to the
human gene (J. Jankevics, unpublished data).
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usage of the two promoters under various stimula-
tory conditions in di¡erent types of T cells.
4. NF-AT factors in Th cell di¡erentiation
4.1. Control of Th1 and Th2 cell di¡erentiation at the
transcriptional level
Peripheral CD4 T helper cells are a heterogene-
ous population of cells which di¡er in the patterns of
lymphokines they secrete. According to their life his-
tory and further criteria, such as the genetic back-
ground, Th cells tend to produce either Th1 lympho-
kines, i.e. IFN-Q, IL-2 and lymphotoxin, or Th2
lymphokines, in particular IL-4, IL-5 and IL-13
(see Fig. 5). Th1 lymphokines are important for pro-
tecting the body against intracellular pathogens, such
as bacteria, while their deregulated expression is in-
volved in the generation of autoimmune diseases. In
contrast, Th2 lymphokines are necessary to eradicate
infections with extracellular parasites, such as para-
sitic worms, and their deregulation leads to asthma
and a number of other allergic diseases.
The prototypes of Th1 lymphokines, IFN-Q, and of
Th2 lymphokines, IL-4, are not only the ¢nal prod-
ucts of Th e¡ector cells but also play important roles
in the di¡erentiation of naive Th0 cells to either Th1
or Th2 cells (see [96] for a review). Whereas IFN-Q
stimulates, by increasing IL-12 receptor expression,
the action of IL-12 which controls Th1 development
through STAT4, IL-4 is a direct stimulator of
STAT6. Both STAT4 and STAT6 are important
control molecules for the commitment of Th0 cells
to Th1 or Th2 cells, respectively. This has been
shown by the creation of STAT4-de¢cient mice
Fig. 5. The role of transcription factors in the di¡erentiation of naive T helper cells to Th1 and Th2 cells. Stimulation of a naive
T cell through its T cell receptor and either the IL-12 or IL-4 receptor drives this cell to di¡erentiate into Th1 or Th2 cells which syn-
thesize either IFN-Q, IL-2 and lymphotoxin, or IL-4, IL-5, IL-6, IL-9, IL-10 and IL-13. Transcription factors which are involved in
the commitment of naive T cells to Th1 or Th2 cells are STAT4 and STAT6, respectively. Inactivation of STAT4 led to severe defects
in Th1 development [97,98], inactivation of STAT6 to defects in Th2 development [99,100]. Bcl-6 is a negative regulator of Th2 devel-
opment counteracting STAT6 activity [127]. T-bet and GATA-3 are T cell commitment factors that also control the expression of
lymphokine genes in T e¡ector cells. While repressing the synthesis of Th2-type lymphokines the expression of T-bet led to a strong
stimulation of IFN-Q expression [107]. In contrast, GATA-3 is an inducer of Th2-type and suppressor of Th1-type responses [103].
NF-AT2, on the other hand, exerts a positive function in di¡erentiation of naive T cells to both Th1 and Th2 cells, and its activity
stimulates both Th1- and Th2-type lymphokines. NF-AT1 (and NF-AT4) is also a positive regulator of all lymphokine promoters but
its inactivation in mice led to an increase in synthesis of Th2-type lymphokines indicating that NF-AT1 (and NF-AT4) might control
a repressor of Th2 di¡erentiation (see Section 4.2).
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which were unable to develop Th1 cells [97,98], and
STAT6-de¢cient mice which showed a severe reduc-
tion in Th2 development and Th2 responses, such as
in the switch to IgE synthesis [99,100].
Both STAT factors are involved in the early
phases of Th commitment to Th1 or Th2 cells. One
of the earliest steps in murine Th2 cell development
is the ‘opening’ of chromatin at the chromosomal
locus 11q which harbors the linkage group of IL-4,
IL-5 and IL-13 genes. While activation of naive
T cells from wild type mice led to a coordinate ap-
pearance of several DNase I hypersensitive chroma-
tin sites after IL-4 treatment around and within the
IL-4 and IL-13 genes, such alterations in chromatin
structure were found to be strongly suppressed in
T cells from STAT6-de¢cient mice [101]. The sup-
pression of chromatin changes could be partially re-
verted by infecting STAT6-de¢cient T cells with a
retrovirus expressing GATA-3 [102]. GATA-3 was
also found to be predominantly expressed in Th2
but not Th1 cells, to facilitate Th2 lymphokine syn-
thesis in Th1 cells from transgenic mice overexpress-
ing GATA-3 [103], to stimulate IL-4 and IL-5 tran-
scription [104,105] and to inhibit Th1 di¡erentiation
[106]. GATA-3 binds to NF-AT2, and the interplay
between NF-AT2, GATA-3 and further factors leads
to the strong induction of IL-5 promoter activity in
T cells (S. Klein-Hessling et al., in preparation). All
these properties indicate GATA-3 as an important
transcription factor whose activity commits naive
T cells to develop into Th2 e¡ector cells in which
GATA-3 also enhances the expression of numerous
lymphokine genes.
T-bet, a member of the family of T box transcrip-
tion and di¡erentiation factors, appears to play an
analogous role in Th1 cell development as GATA-3
does in Th2 cell polarization. Isolated in a yeast one
hybrid screen using a Th1 cDNA library and the IL-
2 promoter [107], T-bet was shown (1) to be predom-
inantly expressed in Th1 cells, (2) to stimulate the
activity of the IFN-Q promoter, (3) to increase
IFN-Q production after retroviral overexpression in
primary Th cells and developing Th2 cells, and (4) to
repress IL-4 (and IL-5) synthesis in developing Th2
cells and Th2 clones. All these properties classify T-
bet as a ‘master regulator’ of Th1 cell di¡erentiation
[107].
In Fig. 5, several further transcription factors have
been compiled whose activity modulates the expres-
sion of Th1- and Th2-type lymphokines and/or Th
cell development. Although the expression of IRF-1
is not restricted to T cells its inactivation in mice
resulted in a failure to generate Th1 cells [108,109].
Moreover, ERM, an Ets family member, was shown
to be induced by IL-12 in a STAT4-dependent man-
ner and predominantly expressed in Th1 cells. On its
own it was, however, unable to stimulate the expres-
sion of Th1 type lymphokines [110].
c-Maf is a member of basic region/leucine zipper
factors which is speci¢cally expressed in Th2 but not
in Th1 cells. Its inactivation led to severe defects in
the production of IL-4 [111]. Moreover, overexpres-
sion of c-Maf in transgenic mice promoted Th2 and
attenuated Th1 cell development [112]. However, in
contrast to GATA-3, c-Maf does not a¡ect the ex-
pression of other Th2-type lymphokines lending sup-
port to the view that c-Maf might control Th2 cell
development by selectively inducing IL-4 expression
[111]. Similar to c-Maf, members of the C/EBP fac-
tor family, such as C/EBPL, bind to the IL-4 pro-
moter [113] and are potent inducers of endogenous
IL-4 expression when inducibly overexpressed in
T tumor cells, e.g. in EL-4 cells, or primary T cells.
They also suppress the synthesis of IL-2 and IFN-Q
RNAs while they do not a¡ect those of other Th2
type lymphokines [130]. However, overexpression of
C/EBPL also leads to the arrest of T cells in the G1
phase of the cell cycle and to apoptosis, which so far
has prevented a more detailed analysis of C/EBPL
function in Th development. NIP45 is an NF-AT
interacting protein which, along with NF-AT and
c-Maf, was shown to stimulate IL-4 synthesis in
B cells [114]. Contrary to other members of the
AP-1 family, JunB was found to be selectively in-
duced during di¡erentiation in Th2 but not Th1 cells.
Upon phosphorylation by JNK kinases, JunB acted
in synergy with c-Maf in stimulating IL-4 expression,
and expression of a JunB transgene in Th1 cells led
to an increase of IL-4, IL-5, IL-6 and IL-10 synthe-
sis, i.e. of lymphokines that are predominantly syn-
thesized in Th2 cells [115].
4.2. NF-AT factors and the control of Th1 and
Th2 cell di¡erentiation
The important role NF-AT factors play in the in-
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duction of numerous lymphokine genes suggests an
important role of NF-ATs in ¢nal Th development
as well. However, experimental results obtained for
mice de¢cient for NF-AT factors (see Table 1) do
not in each case show a close correlation between
the loss of an individual NF-AT protein and loss
of Th1 and/or Th2 function. Due to defects in the
generation of cardiac valves and septa, NF-AT2-de-
¢cient mice die in utero before day 13.5 of gestation
[116,117]. Apart from defects in proliferation, periph-
eral NF-AT23=3 lymphocytes from chimeric RAG/
NF-AT23=3 mice generated by injection of NF-
AT23=3 ES cells into RAG3=3 blastocytes showed
a reduced synthesis of IL-4 (and IL-6) and serum IgE
[42,43]. In addition NF-AT23=3 T cells from one of
the two established mouse strains synthesized more
IL-2 than wild-type T cells after secondary stimula-
tion [42] whereas no increase in IL-2 (and TNFK)
synthesis was detected after primary stimulation of
lymph node T cells from the second NF-AT23=3
mouse strain [43]. However, T cells from transgenic
mice expressing a dominant-negative version of NF-
AT4 were found to secrete less IL-2 than wild-type
T cells [118]. Similarly, infection of mice transgenic
for a dominant-negative version of NF-AT2 with
Mycobacterium bovis, a pathogen which induces
Th1 responses (see [119]), led to a distinct decrease
in INF-Q secretion of transgenic T cells. In these cells,
the generation of nuclear NF-AT complexes is im-
paired. Also, infection of those mice with the para-
sitic worm Nippostrongylus brasiliensis, which in-
duces Th2 responses, resulted in a drastic drop in
IL-4 and IL-5 secretion by transgenic T cells (T.
Twardzik, K. Erb et al., in preparation). All these
results indicate that, in addition to its function in
the control of the cell cycle, NF-AT2 plays an im-
portant role in controlling the generation of both
Th1 and Th2 e¡ector cells.
Contrary to the expectation that NF-AT13=3 mice
would su¡er from severe immunode¢ciencies, even
enhanced immune responses and increased numbers
of lymphocytes were observed in NF-AT13=3 mice,
depending on their age. NF-AT13=3 mice older than
3 months developed a moderate splenomegaly [39,40]
and alterations in thymus morphology [120]. In the
periphery, there was an approximately twofold in-
crease in numbers of T cells, many of which were
CD69 CD44highCD62Lhigh [120], indicative of ‘pre-
activation’. NF-AT13=3 lymph node T cells showed
a 3^4-fold increase in secondary immune response
after ovalbumin sensitization [40], or after either
superantigen (SEA) or anti-CD3 stimulation [120].
In addition, CD4 VL11 T cells from NF-AT13=3
mice showed a retarded deletion after SEA treat-
ment, although there was no detectable di¡erence
in Fas-mediated apoptosis [120] typical for activated
T cells from IL-2-de¢cient mice [121]. A further fea-
ture of all three NF-AT13=3 mouse strains estab-
lished is the dysregulated synthesis of IL-4 which,
in part, seems to be responsible for the enhanced
Th2 responses of NF-AT13=3 mice. However, the
increase in the production of IL-4 and further Th2-
type lymphokines does not appear to be a direct
e¡ect of NF-AT1 de¢ciency on the expression of
these lymphokines. Lymphocytes from two di¡erent
NF-AT13=3 strains showed a decrease in early IL-4
mRNA synthesis [39,41] whereas at later time points
an increase in IL-4 mRNA levels and IL-4 secretion
was observed [39,50]. The increase in IL-4 synthesis
is accompanied by enhanced Th2 responses, such as
increased levels of serum IgE, stronger allergic re-
sponses, enhanced eosinophilia and susceptibility to
Leishmania major infection [39,40,50,122]. In con-
trast, stimulation of Th1 responses in NF-AT13=3
mice by Mycobacterium infection resulted in a im-
paired IFN-Q production indicating that, similar to
NF-AT2, NF-AT1 is also important for the develop-
ment of Th1 cells (K. Erb, T. Twardzik et al., in
preparation).
While inactivation of the NF-AT4 gene which is
highly expressed in thymus does not seem to a¡ect
Th development [123] a drastic increase in the syn-
thesis of IL-4, IL-5, IL-6, IL-10 and GM-CSF cyto-
kines was observed for T cells from NF-AT1+4 dou-
ble-de¢cient mice after anti-CD3 stimulation whereas
the synthesis of IL-2 and IFN-Q was found to be
reduced [44]. This enormous increase in the synthesis
of Th2-type lymphokines was correlated with hyper-
proliferation of peripheral lymphocytes and spleno-
megaly while the induction of Fas ligand and, there-
fore, Fas-mediated apoptosis were found to be
suppressed. In addition, NF-AT1+4 double-de¢cient
mice developed disease symptoms in several organs,
including allergic blepharitis, pneumonitis and lym-
phadenopathy. At the molecular level, NF-AT1+4
de¢ciency led to the constitutive nuclear appearance
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of the short NF-AT2/A isoform [44] whose expres-
sion is a typical sign of activated T e¡ector cells [17].
5. Conclusions
The family of genuine NF-AT proteins consists of
four transcription factors. These show both overlap-
ping and individual functions. The overlapping func-
tions are re£ected in (1) their highly conserved DNA
binding domains which are very similar in three-di-
mensional structure to the Rel domains of NF-UB
factors, and (2) their regulatory, calcineurin binding
regions which contain clusters of Ser/Thr phosphor-
ylation sites whose state of phosphorylation is con-
trolled by calcineurin and, in turn, appears to control
the conformation, residence and, probably, the inter-
action of NF-ATs with other factors and their tran-
scriptional activation. All lymphokine promoters
which are active in T lymphocytes are controlled
by NF-AT factors. However, lymphokine genes are
not the only targets of NF-AT factors in T cells. In
addition to the expression of several receptor and
ligand genes, such as the genes encoding the Fas
and CD40 ligands and the IL-2 receptor K chain/
CD25, NF-AT factors also control the activity of
the proximal lck promoter, the Egr2 and 3 promoters
and, in all likelihood, the inducible NF-AT2 pro-
moter. Moreover, several lines of evidence suggest
that NF-AT factors are major players in the control
of the cell cycle, apoptosis and, probably, cancero-
genesis of T cells. It remains to be shown which
genes controlling these processes are under NF-AT
control, and how this control is achieved, e.g. by
which individual NF-AT factor, through binding to
di¡erent partners, through di¡erent modes of induc-
tion or di¡erent threshold levels. The application of
novel experimental techniques, such as the potent
DNA microarray technology for the analysis of
genes expressed in T cells transgenic or de¢cient for
NF-ATs, will help to elucidate which target genes
and, therefore, which steps in the life cycle of a
T lymphocyte are controlled by NF-AT factors.
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